Malaria-eliminating countries achieved remarkable success in reducing their malaria
burdens between 2000 and 2010. As a result, the epidemiology of malaria in these settings …

Background Chloroquine is the first-line treatment for Plasmodium vivax malaria in most
endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is …

Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

Abstract Background Treatment of Plasmodium vivax malaria requires the clearing of
asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared …

Over recent years, progress in molecular markers for genotyping malaria parasites has
enabled informative studies of epidemiology and transmission dynamics. Results have …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

Emerging antimalarial drug resistance may undermine current efforts to control and
eliminate Plasmodium vivax, the most geographically widespread yet neglected human …

The diagnosis and treatment of Plasmodium vivax malaria differs from that of Plasmodium
falciparum malaria in fundamentally important ways. This article reviews the guiding …

Background Schistosomiasis and STH are among the list of neglected tropical diseases
considered for control by the WHO. Although both diseases are endemic in Zimbabwe, no …

Traditionally, infection with Plasmodium vivax was thought to be benign and self-limiting,
however, recent evidence has demonstrated that infection with P. vivax can also result in …